# KLOW Peptide — Anti-Inflammatory Arm First: A Four-Peptide Research Blend Readout > KLOW peptide co-formulates KPV, GHK-Cu, BPC-157 and TB-500 in one research vial. This is a plain-English readout of the component literature — no blend study on record, the KPV anti-inflammatory arm read first. A plain-spoken laboratory readout of the KPV, GHK-Cu, BPC-157 and TB-500 component literature. Each finding attributed to its source. The missing blend data flagged in the margin. ## In plain English KLOW peptide is a research blend — four different peptides combined in one vial. The four are KPV (an anti-inflammatory tripeptide), GHK-Cu (a copper-carrying tripeptide linked to skin and tissue repair), BPC-157 (a 15-amino-acid peptide studied for tendon and gut healing in rodents), and TB-500 (a short synthetic fragment of a protein called thymosin beta-4, studied for wound closure and muscle repair). No single molecule. No one combined drug. Four separate peptide molecules dissolved together at fixed amounts. The most important thing to understand upfront: no controlled study has ever tested the four-peptide KLOW blend as a combination. Every claim about what KLOW does as a stack is an extrapolation from studies on each component alone — mostly in cells and rodents. This site documents that component literature carefully, flags what the evidence actually supports, and keeps the honest gap — the missing blend data — plainly in view. KLOW is not approved by the FDA and is not a weight-loss or metabolic compound. It is a research-only co-formulation. What people use it for in research contexts, what the component studies have actually measured, and what to watch for — including the safety and anti-doping flags — are on [the effects page](/effects). ## KLOW peptide blend: four arms, one readout KLOW peptide is a co-formulated, lyophilized research blend of four chemically distinct peptides. The most widely cited research-vial composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. The four components do not fuse into a single molecule — they are co-dissolved at these fixed ratios and remain four separate chemical species in solution. The designation 'KLOW' is not a registered pharmaceutical name. No FDA-approved, pharmacopeial, or otherwise regulated KLOW combination product exists. The blend is supplied strictly as a research chemical co-formulation. Each component occupies a distinct node in the tissue-repair signaling network: KPV suppresses innate-immune transcription through NF-kappaB (a protein complex that controls the switch for many inflammatory genes) and MAPK (a signaling pathway involved in cell responses to stress and cytokines) with uptake mediated by the gut-epithelial PepT1 transporter (SLC15A1, a protein that pulls small peptides into intestinal cells); GHK-Cu acts at the transcriptome level toward matrix synthesis and antioxidant defense while supplying copper for collagen crosslinking; BPC-157 drives the VEGFR2/PI3K/Akt/eNOS angiogenic pathway (the signaling chain that builds new blood vessels); and TB-500 sequesters G-actin (monomeric actin, the building block of cell movement scaffolds) through the LKKTET motif, a step linked to cell migration and re-epithelialization. The combination rationale is that these four arms address cytokine suppression, matrix remodeling, new blood-vessel supply, and cytoskeletal mobility as complementary steps of the same repair cascade. What the combination has not done, as of this writing, is appear in any controlled in-vivo or human study as KLOW. All synergy claims are mechanistic extrapolations from the single-component literature — a fact this readout carries as an explicit marker on every blend-level claim. ## KLOW peptide blend: the anti-inflammatory arm leads The lens allocated to this site is anti-inflammatory — and KPV earns that position. The tripeptide Lys-Pro-Val is the C-terminal residues 11–13 of alpha-melanocyte-stimulating hormone (alpha-MSH). At nanomolar concentrations, KPV inhibits NF-kappaB nuclear import in intestinal epithelial and immune cells and suppresses TNF-alpha, IL-6, IL-1beta and IL-8 output [3]. It is actively transported into inflamed gut epithelium and macrophages by PepT1 (SLC15A1), with a Km of approximately 160 micromolar — a biochemical feature that gives it tissue-selective delivery at sites of intestinal inflammation [3]. In murine colitis models, orally administered KPV reduced NF-kappaB and MAPK activation and the severity of DSS- and TNBS-induced colitis [3]. A 2008 mechanistic study found KPV's anti-inflammatory effect in a peritonitis model to be mechanistically distinct from the core alpha-MSH peptides — likely directed at IL-1beta function rather than melanocortin receptors [9]. Murine IBD data showed earlier recovery, reduced myeloperoxidase activity and diminished inflammatory infiltrate, with activity retained in MC1R-deficient animals [10]. A 2024 PepT1-targeted nanoparticle study further demonstrated that co-delivering KPV via a PepT1-directed carrier with the immunosuppressant FK506 restored tight-junction proteins and reduced cytokines more than either agent alone in acute and chronic colitis [12]. Taken together, the KPV literature establishes a well-mechanised anti-inflammatory and mucosal-healing profile in preclinical models. No KPV monotherapy trial has reached regulatory approval, and no human data exist for systemic KPV administration. The anti-inflammatory arm of KLOW is, at this point, a rodent and cell-culture story — a strong one, but not a human one. ## What the remaining three channels measure **GHK-Cu — the matrix and transcriptome arm.** GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II) complex, CAS 89030-95-5) is mass-dominant, making up roughly 62.5% of the canonical vial by weight. It stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin, and its plasma levels decline from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 [4]. A bioinformatic analysis of GHK's gene-expression signature found it modulates approximately 31% of human protein-coding genes at a 50%-or-greater threshold, with its strongest signals on extracellular-matrix remodeling, antioxidant defense, DNA repair, and the ubiquitin-proteasome system [5]. A 2025 rodent colitis study showed GHK-Cu reduced colonic damage and pro-inflammatory cytokines through the SIRT1/STAT3 pathway while restoring the epithelial barrier [13]. **BPC-157 — the angiogenic and tendon repair arm.** BPC-157 (Body Protection Compound 157, CAS 137525-51-0) accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and histological measures and stimulated tendocyte outgrowth in vitro at doses of 10 micrograms, 10 nanograms, or 10 picograms per rat [2]. Its mechanism runs through the VEGFR2/PI3K/Akt/eNOS pathway and a nitric-oxide modulation partly resistant to L-NAME inhibition. A 2025 first-in-human IV safety pilot administered BPC-157 up to 20 mg intravenously in two healthy adults and reported no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers — a very small dataset, but the first human safety signal [6]. **TB-500 — the cytoskeletal and wound-closure arm.** TB-500 (Ac-LKKTETQ, MW 889.02 Da) is an N-acetylated heptapeptide fragment derived from the 43-amino-acid native protein thymosin beta-4. The LKKTET actin-binding motif sequesters G-actin, a step linked to cell migration and wound closure. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline [1]. Most of this data is for full-length thymosin beta-4, not the shorter TB-500 fragment — a distinction the literature requires. A 2024 review confirmed that thymosin beta-4 operates through pro-resolving inflammation pathways [11]. ## The honest gap and what it means No controlled study has ever tested the four-peptide KLOW blend against monotherapy, any subset, or placebo. That single fact sets a ceiling on how much any blend-level claim can be trusted. Additionally, a pharmacokinetic mismatch is inherent in the combination: the two tripeptides KPV and GHK-Cu clear far faster than the larger BPC-157 (which has a short elimination half-life of under approximately 30 minutes in formal PK studies), and the TB-500 fragment behaves differently from the full-length thymosin beta-4 protein. A single co-formulated dose cannot hold all four components at matched plasma exposures simultaneously. For [KLOW research](/research) on the component signals, and for the reported effects — both the benefits people describe and the safety flags worth knowing — the [KLOW effects](/effects) page carries both layers clearly labeled. --- A plain-spoken laboratory readout of the four-peptide component literature — each finding attributed to its source, the missing blend assay marked plainly in the margin.